Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 5
1966 3
1967 5
1968 5
1969 6
1970 11
1971 8
1972 28
1973 20
1974 24
1975 27
1976 29
1977 13
1978 10
1979 19
1980 24
1981 22
1982 30
1983 30
1984 39
1985 55
1986 49
1987 57
1988 65
1989 77
1990 75
1991 93
1992 67
1993 73
1994 78
1995 74
1996 104
1997 99
1998 120
1999 128
2000 125
2001 128
2002 167
2003 135
2004 141
2005 165
2006 166
2007 141
2008 154
2009 172
2010 192
2011 205
2012 237
2013 263
2014 253
2015 246
2016 253
2017 285
2018 293
2019 270
2020 318
2021 377
2022 328
2023 264
2024 90

Text availability

Article attribute

Article type

Publication date

Search Results

6,292 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Beta-thalassemia-X-linked thrombocytopenia syndrome"
Page 1
How Can I Manage Thrombocytopenia in Hemodialysis Patient? A Review.
Guo Q, Lou Y, Liu L, Luo P. Guo Q, et al. Ther Apher Dial. 2020 Aug;24(4):352-360. doi: 10.1111/1744-9987.13448. Epub 2019 Dec 2. Ther Apher Dial. 2020. PMID: 31661590 Review.
In most patients, the platelet count can be maintained within the normal range, and the occurrence of thrombocytopenia is relatively rare in clinical practice. Therefore, the possibility of thrombocytopenia in HD patients is often ignored. Moreover, thromb …
In most patients, the platelet count can be maintained within the normal range, and the occurrence of thrombocytopenia is relatively …
COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome.
Franchini M, Liumbruno GM, Pezzo M. Franchini M, et al. Eur J Haematol. 2021 Aug;107(2):173-180. doi: 10.1111/ejh.13665. Epub 2021 Jun 9. Eur J Haematol. 2021. PMID: 33987882 Free PMC article. Review.
Very rare cases of thrombosis associated with thrombocytopenia have occurred following the vaccination with AstraZeneca COVID-19 vaccine. The aim of this concise review is to summarize the current knowledge on the epidemiologic and pathogenic mechanisms of this syndrome …
Very rare cases of thrombosis associated with thrombocytopenia have occurred following the vaccination with AstraZeneca COVID-19 vacc …
The diagnosis and management of the haematologic manifestations of lupus.
Velo-García A, Castro SG, Isenberg DA. Velo-García A, et al. J Autoimmun. 2016 Nov;74:139-160. doi: 10.1016/j.jaut.2016.07.001. Epub 2016 Jul 25. J Autoimmun. 2016. PMID: 27461045 Review.
Most treatment evidence is based on case-reports or small retrospective studies, as few randomized controlled trials have been performed. The development of biological therapy has opened new possible ways to treat the most severe cases but further clinical trials ar …
Most treatment evidence is based on case-reports or small retrospective studies, as few randomized controlled trials have been perfor …
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, Moore K, O'Reilly EM, Ray-Coquard I, Alexandre J. Morice PM, et al. Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18. Lancet Haematol. 2021. PMID: 33347814
However, some concerns have emerged regarding rare and delayed adverse events including cases of myelodysplastic syndrome and acute myeloid leukaemia, for which data are scarce. The aim of this study was to estimate the risk of myelodysplastic syndrome and acute mye …
However, some concerns have emerged regarding rare and delayed adverse events including cases of myelodysplastic syndrome and acute m …
Eltrombopag.
Bussel JB, Pinheiro MP. Bussel JB, et al. Cancer Treat Res. 2011;157:289-303. doi: 10.1007/978-1-4419-7073-2_17. Cancer Treat Res. 2011. PMID: 21052963 Review.
Discovered in the middle of last decade, followed by experiments in mice and then approved in humans, Eltrombopag is the first TPO-r mimetic available. It has been used and validated in several clinical studies in different etiologies of thrombocytopenia, including …
Discovered in the middle of last decade, followed by experiments in mice and then approved in humans, Eltrombopag is the first TPO-r mimetic …
Heparin-induced thrombocytopenia.
Lovecchio F. Lovecchio F. Clin Toxicol (Phila). 2014 Jul;52(6):579-83. doi: 10.3109/15563650.2014.917181. Epub 2014 May 20. Clin Toxicol (Phila). 2014. PMID: 24844576 Free article. Review.
Abstract A summary of heparin-induced thrombocytopenia (HIT) is presented. HIT is an adverse drug reaction characterized by thrombocytopenia and a high risk for venous or arterial thrombosis. ...HIT was reviewed using a pubmed search; google scholar using key words: …
Abstract A summary of heparin-induced thrombocytopenia (HIT) is presented. HIT is an adverse drug reaction characterized by thromb …
Thrombocytopenia.
Gauer RL, Braun MM. Gauer RL, et al. Am Fam Physician. 2012 Mar 15;85(6):612-22. Am Fam Physician. 2012. PMID: 22534274 Free article.
These patients most likely have an acute infection, heparin-induced thrombocytopenia, liver disease, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, disseminated intravascular coagulation, or a hematologic disorder. During pregnancy, preeclampsia and …
These patients most likely have an acute infection, heparin-induced thrombocytopenia, liver disease, thrombotic thrombocytopenic purp …
COVID-19: Vaccine-induced immune thrombotic thrombocytopenia.
Danish FI, Rabani AE, Subhani FE, Yasmin S, Koul SS. Danish FI, et al. Eur J Haematol. 2022 Dec;109(6):619-632. doi: 10.1111/ejh.13855. Epub 2022 Sep 30. Eur J Haematol. 2022. PMID: 36030503 Free PMC article. Review.
Since the hallmark of this syndrome is the development of thrombocytopenia and/or thrombosis between 4 and 42 days after receiving a COVID-19 vaccine, it was named vaccine-induced immune thrombotic thrombocytopenia (VITT). Other names include "vaccine-induced …
Since the hallmark of this syndrome is the development of thrombocytopenia and/or thrombosis between 4 and 42 days after recei …
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
PURPOSE: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. ...CONCLUSION: Eltrombopag was effective and relatively safe in low-risk MDS with severe thrombocytopenia. This trial is registered with ClinicalTri …
PURPOSE: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. ...CONCLUSION: Eltromb …
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Urban P, et al. Eur Heart J. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372. Eur Heart J. 2019. PMID: 31116395 Free PMC article.
Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. . …
Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a …
6,292 results